Quiliano Miguelmiguel, Valdivia-Olarte Hugo, Olivares Carlos, Requena David, Gutiérrez Andrés H, Reyes-Loyola Paola, Tolentino-Lopez Luis E, Sheen Patricia, Briz Verónica, Muñoz-Fernández Maria A, Correa-Basurto José, Zimic Mirko
Laboratorio de Bioinformática y Biología Molecular, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia. Av. Honorio Delgado, 430. SMP. Lima, Peru ; Drug R&D Unit, Center for Applied Pharmacobiology Research, University of Navarra, C/ Irunlarrea s/n, 31008, Pamplona, Spain.
Bioinformation. 2013 Jul 17;9(13):673-9. doi: 10.6026/97320630009673. Print 2013.
The pandemic influenza AH1N1 (2009) caused an outbreak of human infection that spread to the world. Neuraminidase (NA) is an antigenic surface glycoprotein, which is essential to the influenza infection process, and is the target of anti-flu drugs oseltamivir and zanamivir. Currently, NA inhibitors are the pillar pharmacological strategy against seasonal and global influenza. Although mutations observed after NA-inhibitor treatment are characterized by changes in conserved amino acids of the enzyme catalytic site, it is possible that specific amino acid substitutions (AASs) distant from the active site such as H274Y, could confer oseltamivir or zanamivir resistance. To better understand the molecular distribution pattern of NA AASs, we analyzed NA AASs from all available reported pandemic AH1N1 NA sequences, including those reported from America, Africa, Asia, Europe, Oceania, and specifically from Mexico. The molecular distributions of the AASs were obtained at the secondary structure domain level for both the active and catalytic sites, and compared between geographic regions. Our results showed that NA AASs from America, Asia, Europe, Oceania and Mexico followed similar molecular distribution patterns. The compiled data of this study showed that highly conserved amino acids from the NA active site and catalytic site are indeed being affected by mutations. The reported NA AASs follow a similar molecular distribution pattern worldwide. Although most AASs are distributed distantly from the active site, this study shows the emergence of mutations affecting the previously conserved active and catalytic site. A significant number of unique AASs were reported simultaneously on different continents.
甲型H1N1流感大流行(2009年)引发了一场人类感染疫情,并蔓延至全球。神经氨酸酶(NA)是一种抗原性表面糖蛋白,对流感感染过程至关重要,也是抗流感药物奥司他韦和扎那米韦的作用靶点。目前,NA抑制剂是应对季节性流感和全球流感的主要药理学策略。尽管NA抑制剂治疗后观察到的突变特征是酶催化位点保守氨基酸的变化,但远离活性位点的特定氨基酸替换(AASs),如H274Y,也可能导致对奥司他韦或扎那米韦产生耐药性。为了更好地了解NA AASs的分子分布模式,我们分析了所有已报道的甲型H1N1流感大流行NA序列中的NA AASs,包括来自美洲、非洲、亚洲、欧洲、大洋洲的序列,特别是来自墨西哥的序列。在活性位点和催化位点的二级结构域水平上获得了AASs的分子分布,并在不同地理区域之间进行了比较。我们的结果表明,来自美洲、亚洲、欧洲、大洋洲和墨西哥的NA AASs遵循相似的分子分布模式。本研究汇编的数据表明,NA活性位点和催化位点的高度保守氨基酸确实受到了突变的影响。所报道的NA AASs在全球范围内遵循相似的分子分布模式。尽管大多数AASs分布在远离活性位点的位置,但本研究表明出现了影响先前保守的活性位点和催化位点的突变。在不同大陆同时报道了大量独特的AASs。